SCHEMBL6372247

SCHEMBL6372247

COc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)c(C)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.66
GSK3B P49841 1/20 0.66
KDR P35968 5/20 0.61
BRAF P15056 3/20 0.61
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
HTT P42858 4/20 0.59
LMNA P02545 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
POLB P06746 1/20 0.59
RAB9A P51151 3/20 0.59
MAPT P10636 5/20 0.58
NPSR1 Q6W5P4 2/20 0.57
GRIK1 P39086 3/20 0.57
NPC1 O15118 2/20 0.57
AKR1C3 P42330 1/20 0.57
AKR1C2 P52895 1/20 0.57
MAPK14 Q16539 2/20 0.56
TNNI3K Q59H18 2/20 0.56
IDH2 P48735 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1463349 0.88 GSK3A (0.66) GSK3AGSK3BKDRBRAFMEN1
SCHEMBL1463485 0.86 AKR1C3 (0.70) GSK3AGSK3BMEN1KMT2AHTT
SCHEMBL6378836 0.86 ALDH1A1 (0.67) MEN1KMT2ALMNASMN1; SMN2POLB
SCHEMBL8370207 0.86 GSK3A (0.66) GSK3AGSK3BMEN1KMT2AHTT
SCHEMBL1462402 0.86 NTRK1 (0.69) GSK3AGSK3BKDRBRAFMEN1
SCHEMBL6370472 0.85 MAPT (0.72) GSK3AGSK3BKDRBRAFMEN1
SCHEMBL3181964 0.85 KDR (0.76) KDRBRAFMAPK14TNNI3K
SCHEMBL3676521 0.84 TRPV1 (0.67) KDRMEN1KMT2AHTTLMNA
SCHEMBL13852827 0.84 MEN1 (0.62) KDRMEN1KMT2AHTTLMNA
SCHEMBL6376793 0.83 MEN1 (0.60) KDRMEN1KMT2AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2005-11-10 US claimed
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
WO-2003093250-A2 POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR PHARMACIA & UPJOHN COMPANY (US) 2003-11-13 WO claimed
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2005-11-10 US disclosed
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-16 US disclosed
US-20040249150-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-09 US disclosed
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed
WO-2003093250-A2 POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR PHARMACIA & UPJOHN COMPANY (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 GSK3A 1086/4885GSK3B 1311/4885KDR 3285/4885
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 GSK3A 1086/4885GSK3B 1311/4885KDR 3285/4885
US-20040249150-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 GSK3A 1086/4885GSK3B 1311/4885KDR 3285/4885
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA7, CHRNA1, CHRNA5 GSK3A 727/4885GSK3B 837/4885KDR 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.